Member Info for gtc1507

And yes no amount of r&d updates can substitute contracts now. Need to see execution and conversion and demonstrate the value of these new hires

If I remember right last year wasn't the sequencing the results start of sept and then loads of meets a few weeks later then the day before they announced the NCI results and that they wanted to continue using optimal. I think I read in the Allenby note the results are usually published in August so that timing would align

Haha I'm not saying that with any inside knowledge, just the fact that AIM rules require them to rns something.

If they'd made a deal with NCI that would 100% be material so they'd be breaking the rns rules if they haven't.

Arguably, any rollerover agreement would be of interest to us as investors. Unfortunately, whether it's true or not, the fact that you've gone to Dr Ho for information and got more out of him than the company have said publicly says it all about their comms....

The company will rns when something concrete confirmed

for the NCI, I imagine they're just rolling the interim agreement until the future commercial deal is locked up.

Fair play mm. It lines up with what we know from the company. We also know scientific journals take time but good to see the colour in his language around the company and the ongoing partnership.

Where's that quote from mm

There was a below bid sell yesterday of 20k just before the close. I'm surprised mms didn't mark it down. The real spread is different to the advertised spread. In the absence of volume doenst look like mms want to move it either way

There is no volume. On the plus side no selling. So hopefully when the right news comes buyers will flock to us and we'll see a big move

So they've got US, Japan and Canada in the bag. According to chat gpt that covers 60% of global pharma market so that's good.

Are you suggesting that the 500k is a trader Stan?

Seems stronger today with some buying interest continuing

500k trade just printed - 13:47 @12.05p

Yup - need a big $ sign in the next rns - whether that's for the underlying business or the news exciting things. It's tough out there and the only thing that's gonna convince the market is the big green dollar sign. Hopefully they can convert something soon to restore that confidence. Looks like they're stepping up their marketing on the AI finally.

https://www.linkedin.com/posts/fusionantibodies-antibodies-antibodydiscovery-share-7473325420097179648-fNe4/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAGJLfOABx56jSyhbPFl_DGabxlijALa0vU4&utm_campaign=copy_link

I would obviously caveat that this was just my takeaway from the meeting itself, take with a pinch of salt what you will and do your own research and digging. It all boils down to execution of contracts for optimal and NCI now in my view as well as keeping the underlying ops going

It was asked, he was clear he couldnt cover anything not in public domain but he covered two points broadly .

There's the publication of scientific results from the first studies and trial period from the origisnl 2 year partnership. That appears to be about the scientific publication in journals which would probably be the key scientific validation bit -for the company - he said that can get caught up if NCI are applying for patents they'll want the ok from lawyers before they put anything into the public domain and fusion were balancing the company desire to get things accelerated in terms of marketing with the impact that an NCI owned validation publication would have. Think this was mentioned at the last investor meet company.

That process is apparently be distinct from the negotiation of the future deal however - there were no nuggets of when it would be landing that i recall either way tbh I don't think he could have answered that in a meaningful way,; just that it's more complex when they're seeking economic interest in the assets rather than pure fee for service. He did make the point that they lost a couple of months of progress with the gov shutdown

Coincidentally, it looks like Fairjourney, one of fusions direct competitors went on to buy that asset last year. Looks like their competitors are willing to part with giving big cash for platforms. Given fusion have been poaching their staff maybe they have their eyes out for what fusion are upto and might snaffle up Optimal

https://ghocapital.com/updates/fairjourney-biologics-acquires-charles-river-laboratories-south-san-francisco-facility/

I think a benchmark that was referenced a few years ago at one of the proactive events maybe was the Charles river buyout of distributed bio.

That was for their superhuman phage display platform. If I remember right it went for around $100m in total value.

Optimal itself would appear to have some clear advantages over those earlier technologies and fusion have a range of other technology platforms and assets, like dr5 and those antibodies patented in Japan. So logic would suggest that we could hope for north of that number.

https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-acquires-distributed-bio/

Sounds to me like excellent progress in an area of science that even the big pharma boys are struggling to make impact. According to Richard's video nothing past early trials because of the complexitty of the molecules they're targeting yet their antibody tested against those discontinued and performs much stronger. And today's update confirms that they have data which says it's performing strongly in cancer death assays.

It's a great update and should hopefully make a very attractive licencing opportunity for someone which if successful would likely result in million if not multimillion up fronts and large downstream entitlements.

They do say in their materials that it's their intention to licence it out rather than do any of the trials themselves which would fit with their business model. The fact they've the grant funding to develop it at little cost to us shareholders is brilllaitn too!

I think in the video Richard said Astrazeca, Genmab and Genentech had all tried dr5 before and FABs was better, maybe they'll all sit up and notice at the conference